QGC initiates Phase I study of QGC001 drug
QGC001 is the first of a new class of drugs that can to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The FDA-approved Adcetris is an Antibody Drug Conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE),